|
|
|
| Efficacy of Endo Combined with Liposome Paclitaxel and Cisplatin in the Treatment of Liver Metastases from Lung Cancer |
| YANG Li, HUANG Xun, XIE Jian |
| The First People's Hospital of Yibin, Sichuan Yibin 644000, China |
|
|
|
|
Abstract Objective: To observe the clinical efficacy of Endo combined with liposomal paclitaxel and cisplatin in the treatment of liver metastases from lung cancer. Methods: A total of 125 patients with non-small cell lung cancer (NSCLC) who were admitted to our hospital from January 2018 to December 2019 and were treated with chemotherapy were randomly divided into observation group and control group based on the random number table. In the observation group, 67 cases were treated with "Endo + liposomal paclitaxel + cisplatin"; in the control group, 58 cases were treated with "liposomal paclitaxel + cisplatin". The clinical efficacy of the primary lesions and liver metastases were compared between the two groups, and the occurrence of adverse reactions in the two groups was recorded at the same time, and the two groups were followed up for more than 1 year to record the progression-free survival (PFS). Results: In terms of the efficacy of primary lung lesions, there was no significant difference in overall efficacy, ORR and DCR between the two groups (P>0.05). In terms of the efficacy of liver metastases, compared with the control group, the observation group has better overall clinical efficacy (P<0.05); the observation group has significantly higher ORR (38.81% vs 20.69%) and DCR (85.07% vs 68.97%) (P<0.05). Compared with the control group, the PFS of the observation group was significantly longer (P<0.05); there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Compared with the "liposomal paclitaxel + cisplatin" treatment, Endo combined with liposomal paclitaxel and cisplatin in the clinical treatment of lung cancer liver metastasis is more effective, and effectively inhibits liver metastasis, and it also significantly improves patients progression-free survival, improvs the prognosis of patients, and has clinical application value.
|
|
|
|
|
|
[1] 许田慧,刘宝刚.晚期肺癌肝转移的综合治疗进展[J].现代肿瘤医学,2019,27(12):2200~2203.
[2] Moataz, Reda, Worapol, et al. PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer. [J]. Cancer letters, 2019, 467:9~18.
[3] 吴炳群,魏慎海,田进涛,等.不同转移部位的非小细胞肺癌患者的生存时间比较[J].中国肺癌杂志,2019,22(2):105~110.
[4] Jie,Yang, Aimei,Peng, Bo,Wang, et al. The prognostic impact of lymph node metastasis in patients with non-small cell lung cancer and distant organ metastasis.[J].Clinical & experimental metastasis, 2019, 36(5):457~466.
[5] Baiying,Li,Wenyue,Gu, Xinhai,Zhu. NEAT1 mediates paclitaxel-resistance of non-small cell of lung cancer through activation of Akt/mTOR signalling pathway. [J]. Journal of drug targeting, 2019, 27(10):1061~1067.
[6] Qian,Han, Peng,Cheng, Hongjie,Yang, et al. Altered expression of microRNA-365 is related to the occurrence and development of non-small-cell lung cancer by inhibiting TRIM25 expression. [J]. Journal of cellular physiology, 2019, 234(12):22321~22330.
[7] 曹永清,刘冀衡,李科,等.Endostatin、VEGF在恩度联合化疗治疗NSCLC不同疗效患者间的表达差异及分析[J].中国医师杂志,2018,20(7):999~1001,1005.
[8] 朱丽娜,谢宝杰,殷风华,等.紫杉醇酯质体联合顺铂动脉灌注治疗晚期非小细胞肺癌的临床探讨[J].中国急救医学,2017,37(z1):164~165.
[9] 徐彩虹,陈俊.恩度联合静脉化疗对晚期非小细胞肺癌肿瘤标志物和新生血管的影响[J].中国慢性病预防与控制,2018,26(2):124~127.
[10] 沈佳琴,邵秋月,叶英俊,等.恩度联合同期放化疗治疗不可切除Ⅲ期非小细胞肺癌不良反应的观察与护理[J].中华全科医学,2017,15(10):1805~1807. |
|
|
|
2020, Vol. 26 
